Boehringer Ingelheim enters 2024 on a high note: Announcing five new R&D partnerships
Boehringer Ingelheim has kicked off 2024 on a high note by announcing that the company is entering five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Through these strategic partnerships, Boehringer is building on past years successes, including 2023 where the company entered into more than 100 new R&D partnerships.
The five partnerships just unveiled focus on addressing high unmet patient needs across three leading of Boehringer’s focus areas: Oncology, cardio-renal-metabolic and fibro-inflammatory diseases:
- The collaboration with Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) will focus on the development of new mRNAi therapeutics for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) targeting disease-causing genes specifically in liver cells.
- Building on the successful completion of a first partnership, a second partnership with 3T Biosciences will leverage their platform technology for the discovery of novel cancer antigens to expand and accelerate the company’s pipeline of first-in-class T-cell based anti-cancer therapies.
- A license agreement with Enara Bio for multiple novel Non-Small Cell Lung Cancer (NSCLC) antigens and the launch of a further component of the collaboration to initiate antigen discovery in another solid tumor indication.
- The license agreement with Kyowa Kirin will enable the development of novel, first-in-class treatments for fibro-inflammatory diseases.
- Together with Newcastle University and the University of Edinburgh, Boehringer will initiate ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints), the most extensive observational clinical study worldwide to enhance the understanding of NASH cirrhosis and also identify the most promising translational biomarkers.
“We are very excited to share these announcements and look forward to working with our new partners to develop first-in-class treatments options for people living with conditions for which there are limited or no treatment options to date,” said Detlev Mennerich, Global Head of Business Development & Licensing, Boehringer Ingelheim. “With these partnerships we are not only bolstering our R&D portfolio, but also our ability to further accelerate the growth of our highly innovative pipeline by combining the novelty power of our partners with our internal translation expertise and capabilities for scaling.”
Boehringer Ingelheim focuses on addressing unmet patient needs across a wide range of diseases, including cardiovascular, renal and metabolic diseases, central nervous system diseases, immunology and respiratory diseases, cancers and retinal diseases. If you are interested in partnering with Boehringer , please check out this link Partnering | Boehringer Ingelheim (boehringer-ingelheim.com), or reach out to us in-person during this week’s J.P. Morgan Healthcare Conference.
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
